Early detection of multiple cancers using a blood test in healthy individuals
Official title: A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT
Run by Guangzhou Burning Rock Dx Co., Ltd. · NCT05227534 · Data updated 2026-11-12
This study is testing a new blood test to see if it can help find different types of cancer early in healthy people aged 40 to 75 who are at risk.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 75 Years |
| Sex | All |
| Enrollment | 12500 (estimated) |
| Sponsor | Guangzhou Burning Rock Dx Co., Ltd. Industry-sponsored |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | June 1, 2022 |
| Main results expected | March 1, 2024 |
| Study ends | December 31, 2028 |
| Registry record updated | July 6, 2022 |
| Trial ID | NCT05227534 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are asymptomatic individuals aged 40 to 75 who have not undergone certain cancer screenings in the past five years.
✕Probably not a fit
Patients with existing cancer symptoms or those who have recently undergone specific cancer screenings will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PREVENT is a multicenter interventional study that evaluates the effectiveness of the OverC multi-cancer detection blood test in asymptomatic individuals at risk for cancer. Participants aged 40 to 75 will undergo this blood test alongside standard cancer screening methods. The study aims to identify various cancer types and stages through the results of the OverC test, with approximately 12,500 participants enrolled over a 9-month period across 30 clinical sites in China. Follow-up will continue for about 5 years to monitor outcomes.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of multiple cancers, improving treatment outcomes for patients.
How similar studies have gone: Other studies have shown promise in early cancer detection using blood tests, but the specific approach of the OverC test is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must be able to provide a written informed consent form * Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form * Participants must be able to provide blood samples for study tests * Participants must be between 40 and 75 years old Exclusion Criteria: * Individuals who have an acute infection or inflammation within 14 days prior to recruitment * Individuals with cancer-associated clinical symptoms or suspected of cancer * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant * Recipient of blood transfusion within 7 days prior to recruitment * Individuals who have pure ground-glass opacity * Unable to provide blood samples for the multi-cancer early detection blood test * Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests * Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment * Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment * Individuals with hemorrhagic diseases * Individuals with autoimmune diseases * Individuals who are pregnant or lactating * Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
Where it's running
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China Recruiting
Study contacts
- Study coordinator: Shangli Cai
- Email: shangli.cai@brbiotech.com
- Phone: 13811823843
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Empowering patients to get lung cancer screening with support and navigation
This pilot study tests a patient navigation and education program to see if it helps adults who are eligible start and complete low-dose CT lung cancer screening.
-
Breast ultrasound screening for older women in community clinics
This study tests whether offering breast ultrasound to women aged 65–80 in local communities helps find breast cancers earlier than usual care.
-
Text reminders to boost colorectal cancer screening participation
A large group of people aged 50–69 in Vallès Occidental will be randomised to receive a reminder text message five weeks after an initial invitation, to see if it increases uptake of the FIT screening compared with the standard postal letter.
-
Menstrual cup for early detection of endometrial cancer in Lynch syndrome
This project will test whether using a menstrual cup can collect uterine lining samples that help detect early endometrial cancer in menstruating people who carry Lynch syndrome gene changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.